DSpace Repository

Streptococcus pneumoniae serotype 19A in hospitalized children with invasive pneumococcal disease after the introduction of conjugated vaccines in Lima, Peru.

Show simple item record

dc.contributor.author Ochoa Woodell, Theresa Jean
dc.contributor.author Del Águila, Olguita
dc.contributor.author Reyes, Isabel
dc.contributor.author Chaparro Dammert, Luis Eduardo
dc.contributor.author Castillo Díaz, María Esther
dc.contributor.author Campos, Francisco
dc.contributor.author Saenz, Andrés
dc.contributor.author Hernandez, Roger
dc.contributor.author Luna Muschi, Alessandra Joanna
dc.contributor.author Castillo Tokumori, Franco
dc.contributor.author Montero Quiñe, Andrea Estefania
dc.contributor.author Gonzales Jaimes, Brayan Enrique
dc.contributor.author Mercado Zarate, Erik Hernan
dc.coverage.spatial Lima, Perú
dc.date.accessioned 2023-12-07T22:33:25Z
dc.date.available 2023-12-07T22:33:25Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/14726
dc.description.abstract BACKGROUND: The Pneumococcal conjugate vaccine (PCV) has decreased cases of invasive pneumococcal disease (IPD) worldwide. However, the impact of PCVs introduction may be affected by the serotype distribution in a specific context. METHODS: Cross-sectional multicenter passive surveillance study of IPD cases in pediatric patients hospitalized in Lima, Peru between 2016 and 2019 (after PCV13 introduction) to determine the serotype distribution and antimicrobial resistance of Streptococcus pneumoniae. Serotyping was performed by a sequential multiplex PCR and confirmed by whole genome sequencing. RESULTS: Eighty-five S. pneumoniae isolates were recovered (4.07/100,000 among children <60 months of age). Serotype 19A was the most common (49.4%). Children infected with serotype 19A in comparison with children infected with other serotypes were younger, had a lower rate of meningitis and higher rates of pneumonia, complicated pneumonia and antimicrobial resistance; 28.6% of patients with serotype 19A have received at least one dose of PCV13 vs. 62.8% of patients with other serotypes. Using MIC-breakpoints, 81.2% (56/69) of non-meningitis strains and 31.2% (5/16) of meningitis strains were susceptible to penicillin; 18.8% (3/16) of meningitis strains had intermediate resistance to ceftriaxone. Resistance to azithromycin was 78.8% (67/85). Serotype 19A frequency increased over time in the same study population, from 4.2% (4/96) in 2006-2008, to 8.6% (5/58) in 2009-2011, to 49.4% (42/85) in the current study (2016-2019) (p < 0.001). CONCLUSIONS: After PCV13 introduction in Peru, serotype 19A remains the most prevalent; however, the vaccination coverage is still not optimal. Therefore, additonal surveillance studies are needed to determine the remaining IPD burden. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Journal of Infection and Public Health
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Streptococcus pneumoniae en_US
dc.subject Pneumococcal vaccine en_US
dc.subject Serotype en_US
dc.subject Antimicrobial resistance en_US
dc.subject Children en_US
dc.subject.mesh Streptococcus pneumoniae
dc.subject.mesh Vacunas Neumococicas
dc.subject.mesh Serogrupo
dc.subject.mesh Farmacorresistencia Microbiana
dc.subject.mesh Niño
dc.title Streptococcus pneumoniae serotype 19A in hospitalized children with invasive pneumococcal disease after the introduction of conjugated vaccines in Lima, Peru. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/j.jiph.2023.10.047
dc.relation.issn 1876-035X

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account